Arthrogen
Developing local gene therapy for chronic diseases, Arthrogen utilizes viral-mediated gene transfer to treat conditions like rheumatoid arthritis. Their approach focuses on intra-articular delivery of therapeutic genes for sustained local treatment with minimal systemic side effects. Using adeno-associated virus (AAV) vectors, they are developing and validating new vectors and therapeutic genes, with plans to move […]
uniQure
Pioneering gene therapy, uniQure develops transformative treatments using its AAV-based technology platform. They achieved a landmark approval for their hemophilia B gene therapy, marking a significant advancement in genomic medicine. Building on this success, uniQure is advancing clinical programs for Huntington’s disease and developing a pipeline of preclinical candidates. Orignally spunout as Amsterdam Molecular Therapeutics […]
Phlox Therapeutics
Phlox Therapeutics uses smart RNA designs to target multiple Lamin A/C mutations, offering therapies for rare genetic cardiomyopathies. Their constructs, developed by the group of Amsterdam UMC Professor Yigal Pinto, show promising therapeutic effects in patient-derived cardiomyocytes. Phlox Therapeutics aims to expand their technology to other treatment-resistant cardiomyopathies.
PacingCure
PacingCure is pioneering gene therapy solutions to cure heart conditions that results in pacing issues. The company focuses on developing biological pacemakers for patients who cannot use conventional electronic pacemaker devices. Their research explores various transgenes and delivery systems to modulate heart pacing. PacingCure is dedicated to advancing cardiac care through innovative gene therapy.
